JP6919960B1 - 新規フェニルプロパノイド化合物 - Google Patents
新規フェニルプロパノイド化合物 Download PDFInfo
- Publication number
- JP6919960B1 JP6919960B1 JP2021093326A JP2021093326A JP6919960B1 JP 6919960 B1 JP6919960 B1 JP 6919960B1 JP 2021093326 A JP2021093326 A JP 2021093326A JP 2021093326 A JP2021093326 A JP 2021093326A JP 6919960 B1 JP6919960 B1 JP 6919960B1
- Authority
- JP
- Japan
- Prior art keywords
- compound
- skin
- present
- compound represented
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 phenylpropanoid compound Chemical class 0.000 title description 41
- 229930015704 phenylpropanoid Natural products 0.000 title description 36
- 240000008886 Ceratonia siliqua Species 0.000 claims abstract description 80
- 235000013912 Ceratonia siliqua Nutrition 0.000 claims abstract description 79
- 150000001875 compounds Chemical class 0.000 claims abstract description 54
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 239000012453 solvate Substances 0.000 claims abstract description 15
- 230000002087 whitening effect Effects 0.000 claims description 39
- 230000008099 melanin synthesis Effects 0.000 claims description 38
- 230000003078 antioxidant effect Effects 0.000 claims description 34
- 235000017367 Guainella Nutrition 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 239000003963 antioxidant agent Substances 0.000 claims description 21
- 239000000284 extract Substances 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- 239000002537 cosmetic Substances 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000003112 inhibitor Substances 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000002038 ethyl acetate fraction Substances 0.000 claims description 7
- 239000003208 petroleum Substances 0.000 claims description 7
- 238000000638 solvent extraction Methods 0.000 claims description 7
- 239000000399 hydroalcoholic extract Substances 0.000 claims description 5
- 238000000622 liquid--liquid extraction Methods 0.000 claims description 5
- 235000013913 Ceratonia Nutrition 0.000 claims description 3
- 241001060815 Ceratonia Species 0.000 claims description 3
- 229940043431 ceratonia Drugs 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 abstract description 8
- 238000010586 diagram Methods 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
- 238000000605 extraction Methods 0.000 description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 37
- 238000012360 testing method Methods 0.000 description 30
- 235000006708 antioxidants Nutrition 0.000 description 20
- 239000012488 sample solution Substances 0.000 description 19
- 150000003254 radicals Chemical class 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 16
- 239000013641 positive control Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 208000001382 Experimental Melanoma Diseases 0.000 description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 12
- 238000000862 absorption spectrum Methods 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 230000032683 aging Effects 0.000 description 7
- 238000004896 high resolution mass spectrometry Methods 0.000 description 7
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 230000002292 Radical scavenging effect Effects 0.000 description 6
- 229960005070 ascorbic acid Drugs 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 239000002211 L-ascorbic acid Substances 0.000 description 5
- 235000000069 L-ascorbic acid Nutrition 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 5
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 4
- 244000046052 Phaseolus vulgaris Species 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 239000003456 ion exchange resin Substances 0.000 description 4
- 229920003303 ion-exchange polymer Polymers 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 241000209094 Oryza Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001142 anti-diarrhea Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 238000012916 structural analysis Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- FSWPYMKNTNNDMB-AATRIKPKSA-N CC(C)C(OC/C=C/c(cc1OC)cc(OC)c1O)=O Chemical compound CC(C)C(OC/C=C/c(cc1OC)cc(OC)c1O)=O FSWPYMKNTNNDMB-AATRIKPKSA-N 0.000 description 2
- 241000220486 Caesalpinioideae Species 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000011894 semi-preparative HPLC Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 description 2
- QJVXKWHHAMZTBY-KSXIZUIISA-N syringin Natural products COc1cc(C=CCO)cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O QJVXKWHHAMZTBY-KSXIZUIISA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- LZFOPEXOUVTGJS-ONEGZZNKSA-N trans-sinapyl alcohol Chemical group COC1=CC(\C=C\CO)=CC(OC)=C1O LZFOPEXOUVTGJS-ONEGZZNKSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- LZFOPEXOUVTGJS-UHFFFAOYSA-N cis-sinapyl alcohol Natural products COC1=CC(C=CCO)=CC(OC)=C1O LZFOPEXOUVTGJS-UHFFFAOYSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 239000008271 cosmetic emulsion Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 238000003808 methanol extraction Methods 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229950009195 phenylpropanol Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0204—Specific forms not provided for by any of groups A61K8/0208 - A61K8/14
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Beans For Foods Or Fodder (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
(1)メラニン生成抑制作用及び抗酸化活性を備え、相乗的な美白効果を有する。
(2)古来から食用とされているイナゴマメの莢果由来の化合物を有効成分とするものであるため、人体に対する安全性が高い。
1.イナゴマメ莢果の含水アルコール抽出物の調製
採取後、乾燥処理されたイナゴマメ(Ceratonia siliqua)の莢付果実から種を取り除いた。このイナゴマメの莢果を粉砕機で粉砕して粒径2mm以下の粉砕物を得た。20kgの粉砕物に対し、140kg(7倍量)の含水95%エタノールを加え、1.5時間還流抽出する操作を2回行った後、残渣をさらに140kg(7倍量)の含水70%エタノールで1.5時間還流抽出した。得られた還流抽出液を合わせた後、溶媒を減圧留去してイナゴマメ莢果の含水エタノール抽出物12.4kgを得た。
2.イナゴマメ莢果の含水アルコール抽出物の分離及び精製
実施例1で得られたイナゴマメ莢果の含水エタノール抽出物を1〜10倍量の水に分散させ、イオン交換樹脂(マクロポーラス吸着樹脂D101、Cangzhou Bon Adsorber Technology Co., Ltd.)に吸着させた。カラム容量の3倍量の蒸留水で溶出して糖類等の不純物を除去した後、カラム容量の3倍量の含水95%エタノールで溶出させ、溶媒を減圧留去し、462.7gのエタノール溶出画分(非炭水化物系低分子化合物画分)を得た。次に、得られたエタノール溶出画分を1.0Lの含水50%メタノールに分散させ、石油エーテル、酢酸エチルの順に、それぞれ5回ずつ液液抽出を行った。各溶媒を減圧留去して、石油エーテル画分28.4g、酢酸エチル画分139.4g及び水系画分290.2gをそれぞれ得た。
3.化合物(Ceratonia siliqua B)の構造解析
実施例2で得られた化合物、「Ceratonia siliqua B」の構造解析を行った。構造解析にあたり、高分解能質量分析(HR−ESI−MS;正イオンモード)、紫外吸収スペクトル分析、赤外吸収スペクトル分析、1H−NMR、13C−NMR、HMBC及びHSQC分析を行った。これらの分析に用いた装置は次のとおりである。
・高分解能質量分析:エレクトロスプレーイオン化四重極飛行時間型質量分析装置(Bruker Daltonics社製品)
・紫外吸収スペクトル分析:紫外可視分光光度計(UV−2401PC、株式会社島津製作所製品)
・赤外吸収スペクトル分析:FT−IR(NEXUS470、Thermo nicolet社製品)
・NMR分析:600MHz核磁気共鳴装置(AVANCE III 600、Bruker社製品)
・性状:黄色粉末
・HR−ESI−MS(positive) m/z:465.1983[M+Na]+
・紫外吸収スペクトル:λmax(MeOH)nm (logε):193.6(3.73),211.6(4.32),269.2(3.97)
・赤外吸収スペクトル(KBr、cm−1):νmax:3393.18,2933.52,1731.29,1587.20,1506.71,1464.86,1421.12,1388.81,1336.38,1243.07,1158.97,1129.16,1070.11,625.20,609.78,595.24,581.17,566.35,536.59,523.24
4.Ceratonia siliqua Bの抗酸化活性(1)
実施例2で得たCeratonia siliqua Bを用いて、Ceratonia siliqua BのDPPHラジカル消去活性を測定した。
ラジカル消去率(%)=[Aブランク−(Aサンプル−Aサンプルブランク)]/Aブランク×100
Aブランクはブランクの吸光度、Aサンプルはサンプル液の吸光度、Aサンプルブランクはサンプルブランクの吸光度である。
5.Ceratonia siliqua Bの抗酸化活性(2)
実施例2で得たCeratonia siliqua Bを用いて、Ceratonia siliqua Bが、生細胞中の活性酸素種(Reactive Oxygen Species:ROS)の生成に与える影響を調べた。
本試験においては、生細胞として、ヒト肝由来腫瘍細胞株であるHepG2細胞を用いた。HepG2細胞は、DMEM培地(10%FBS、100U/mLのペニシリン及び100μM/mLストレプトマイシンを含む)で37℃、5%CO2存在下、飽和湿度条件下で培養した。
Ceratonia siliqua BをDMEM培地で希釈し、1μM、5μM、10μM、50μM及び100μMの異なる濃度のサンプル液を得た。
まず、MTT試験により、HepG2細胞に対するCeratonia siliqua Bの細胞毒性の有無の確認を行った。3代以上継代培養されたHepG2細胞をトリプシン処理し、1×105個/mLの濃度の単一細胞の懸濁液を調製した。96ウェルマイクロプレートの各ウェルにこの細胞懸濁液を100μLずつ播種し、CO2インキュベーターで24時間培養した。培養後、上清を除去して、対照(ブランクコントロール)群と試験群とに分け、対照群にはDMEM培地を200μL添加し、試験群には上記(イ)のサンプル液をそれぞれ200μLずつ添加した。CO2インキュベーターで48時間培養した後、上清を除去し、0.5mg/mLのMTTを100μLずつ添加した。4時間後、上清を除去し、DMSOを150μLずつ添加し、マイクロプレートリーダーにて570nmにおける吸光度を測定した。試験は対照群、試験群における各濃度のサンプル液について、3回(3ウェル)ずつ行った(n=3)。
1×105個/mLの濃度のHepG2細胞懸濁液を調製し、96ウェルマイクロプレートの各ウェルにこの細胞懸濁液を100μLずつ播種し、CO2インキュベーターで24時間培養した。これをブランクコントロール群、陽性対照群及び試験群に分け、ブランクコントロール群にはDMEM培地を100μL添加し、陽性対照群にはL−アスコルビン酸をDMEM培地に溶解させた溶液を100μL添加し(L−アスコルビン酸の最終濃度:100μM)、試験群にはCeratonia siliqua BをDMEM培地で適宜希釈した溶液を異なる濃度(最終濃度:1μM、5μM、10μM、50μM及び100μM)となるように100μLずつ添加した。CO2インキュベーターで24時間培養した後、各ウェルから培養液を除去し、無血清培地を100μL加えて洗浄することを3回繰り返した。次に、10μMのDCFH−DA(2',7'-Dichlorofluorescin diacetate)を100μLずつ各ウェルに加え、CO2インキュベーターで60分間インキュベートした後、各ウェルからDCFH−DAを除去し、無血清培地を100μL加えて洗浄することを3回繰り返した。最後に無血清培地で希釈した400μMの過酸化水素(H2O2)を100μLずつ各ウェルに添加し、90分間インキュベートした。その後、ウェル内の培地を除去し、100μLのPBSを加え、励起波長485nmで535nmにおける蛍光強度を測定した。ブランクコントロール群の蛍光強度を1.0(Basal)として、陽性対照群及び試験群のROS生成量を算出した。試験はブランクコントロール群、陽性対照群及び試験群における各濃度のサンプル液について、3回(3ウェル)ずつ行った(n=3)。
6.Ceratonia siliqua Bのメラニン生成抑制効果
実施例2で得たCeratonia siliqua Bを用いて、Ceratonia siliqua Bのメラニン生成抑制効果を調べた。
本試験においては、B16メラノーマ細胞を用いた。B16メラノーマ細胞は、マウス皮膚の黒色腫瘍由来細胞株であり、メラニン産生能を有している。B16メラノーマ細胞は、DMEM培地(10%FBS、100U/mLのペニシリン及び100μM/mLストレプトマイシンを含む)で37℃、5%CO2存在下、飽和湿度条件下で培養した。
Ceratonia siliqua BをDMEM培地で希釈し、1μM、5μM、10μM、50μM及び100μMの異なる濃度のサンプル液を得た。
まず、MTT試験により、B16メラノーマ細胞に対するCeratonia siliqua Bの細胞毒性の有無の確認を行った。3代以上継代培養されたB16メラノーマ細胞をトリプシン処理し、3×104個/mLの濃度の単一細胞の懸濁液を調製した。96ウェルマイクロプレートの各ウェルにこの細胞懸濁液を100μLずつ播種し、CO2インキュベーターで一晩インキュベートした。各ウェルから上清を除去して、対照(ブランクコントロール)群と試験群とに分け、対照群にはDMEM培地を200μL添加し、試験群には上記(イ)のサンプル液をそれぞれ200μLずつ添加した。CO2インキュベーターで48時間培養した後、上清を除去し、0.5mg/mLのMTTを100μLずつ添加した。4時間後、上清を除去し、DMSOを150μLずつ添加し、マイクロプレートリーダーにて570nmにおける吸光度を測定した。試験は対照群及び試験群における各濃度のサンプル液について、3回(3ウェル)ずつ行った(n=3)。
B16メラノーマ細胞の単一細胞の懸濁液を調製し、12ウェルマイクロプレートの各ウェルに4×104個のB16メラノーマ細胞をそれぞれ播種した。CO2インキュベーターで一晩培養した後、上清を除去し、ブランクコントロール群、陽性対照群及び試験群に分けた。ブランクコントロール群にはDMEM培地を1mL添加し、陽性対照群にはL−アスコルビン酸を異なる濃度でDMEM培地に溶解させた溶液(L−アスコルビン酸の濃度:0.1μM、5μM、10μM)を1mLずつ添加し、試験群には上記(イ)のサンプル液をそれぞれ1mLずつ添加した。48時間培養した後、各ウェルから上清を除去し、PBSバッファーで2回洗浄した後、トリプシン処理を行い、1.2mLのPBSバッファーを加えて単一細胞の懸濁液を調製した。この細胞懸濁液のうち200μLを分取し、蛋白質含有量を決定した。また、残りの細胞懸濁液は3000rpmで5分間遠心分離して上清を除去した後、1%DMSOを含む1MのNaOH溶液を250μL加え、80℃に加温したウォーターバスで30分間溶解させた。この溶解液の200μLを取り、405nmにおける吸光度(A試験群、A陽性対照群、Aブランクコントロール群)を測定した。試験はブランクコントロール群、陽性対照群及び試験群における各濃度のサンプル液について、3回(3ウェル)ずつ行った(n=3)。
試験群のメラニンの生成抑制率(%)=1−[(A試験群/試験群の蛋白質含有量)/(Aブランクコントロール群/ブランクコントロール群の蛋白質含有量)]。
陽性対照群のメラニンの生成抑制率(%)=1−[(A陽性対照群/陽性対照群の蛋白質含有量)/(Aブランクコントロール群/ブランクコントロール群の蛋白質含有量)]。
ここで、A試験群は試験群の吸光度、A陽性対照群は陽性対照群の吸光度、Aブランクコントロール群はブランクコントロール群の吸光度である。
Claims (9)
- 前記式(I)で表される化合物若しくはその塩又はそれらの溶媒和物の濃度が0.001mM〜1mMである請求項2に記載の美白剤。
- 皮膚外用剤である請求項2〜5のいずれか1項に記載の剤。
- 化粧料である、請求項2〜6のいずれか1項に記載の剤。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021093326A JP6919960B1 (ja) | 2021-06-03 | 2021-06-03 | 新規フェニルプロパノイド化合物 |
CN202280030063.4A CN117529487B (zh) | 2021-06-03 | 2022-03-14 | 新颖苯丙素类化合物 |
KR1020237033794A KR20240017335A (ko) | 2021-06-03 | 2022-03-14 | 신규 페닐프로파노이드 화합물 |
US18/564,331 US20240270779A1 (en) | 2021-06-03 | 2022-03-14 | Novel phenylpropanoid compound |
PCT/JP2022/011172 WO2022254867A1 (ja) | 2021-06-03 | 2022-03-14 | 新規フェニルプロパノイド化合物 |
EP22815624.6A EP4349844A1 (en) | 2021-06-03 | 2022-03-14 | Novel phenylpropanoid compound |
TW111120853A TW202313063A (zh) | 2021-06-03 | 2022-06-06 | 新穎苯丙烷類化合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021093326A JP6919960B1 (ja) | 2021-06-03 | 2021-06-03 | 新規フェニルプロパノイド化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP6919960B1 true JP6919960B1 (ja) | 2021-08-18 |
JP2022185604A JP2022185604A (ja) | 2022-12-15 |
Family
ID=77269477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021093326A Active JP6919960B1 (ja) | 2021-06-03 | 2021-06-03 | 新規フェニルプロパノイド化合物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20240270779A1 (ja) |
EP (1) | EP4349844A1 (ja) |
JP (1) | JP6919960B1 (ja) |
KR (1) | KR20240017335A (ja) |
CN (1) | CN117529487B (ja) |
TW (1) | TW202313063A (ja) |
WO (1) | WO2022254867A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117529487A (zh) * | 2021-06-03 | 2024-02-06 | 拿波佳尔股份有限公司 | 新颖苯丙素类化合物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116726065A (zh) * | 2023-06-06 | 2023-09-12 | 融致丰生制药有限公司 | 一种角豆树果荚提取物及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011136969A (ja) * | 2009-12-29 | 2011-07-14 | Daiichi Kokusai Kagi Kofun Yugenkoshi | セツレンカ抽出物、飲食品組成物および基礎化粧品組成物 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3415198B2 (ja) * | 1993-06-30 | 2003-06-09 | 三省製薬株式会社 | 皮膚外用剤 |
JP2005119999A (ja) | 2003-10-15 | 2005-05-12 | Sanpo Kk | イナゴマメ抽出物 |
KR20060093164A (ko) * | 2005-02-21 | 2006-08-24 | 주식회사 엘지생활건강 | 주름완화 화장료 조성물 |
EP2063860A1 (en) * | 2006-09-20 | 2009-06-03 | Chanel Parfums Beauté | Cosmetic use of active agents that stimulate matriptase expression |
CN101532950B (zh) * | 2008-12-31 | 2011-09-07 | 程树军 | 利用人类皮肤黑色素细胞分析美白剂毒性和功效的方法 |
CN101696202B (zh) * | 2009-10-28 | 2012-05-02 | 云南民族大学 | 一种红景天所含苯丙素类化合物及其制备方法和应用 |
FR2954697B1 (fr) * | 2009-12-24 | 2016-11-04 | Isp Investments Inc | Composition cosmetique et/ou pharmaceutique comprenant un extrait de caroube en tant qu'agent actif activateur de l'expression des aquaporines |
CN106046071B (zh) * | 2016-03-17 | 2018-11-16 | 株洲千金药业股份有限公司 | 一种苯丙素类化合物的制备方法 |
CN105884841B (zh) * | 2016-03-17 | 2018-09-25 | 株洲千金药业股份有限公司 | 一种苯丙素类化合物的制备方法 |
CN111995645B (zh) * | 2020-08-06 | 2022-03-18 | 江苏康缘药业股份有限公司 | 一种苯丙素类化合物及其制备方法和应用 |
JP6976014B1 (ja) * | 2021-04-09 | 2021-12-01 | 株式会社ナボカルコスメティックス | 新規ポリフェノール化合物 |
JP6919960B1 (ja) * | 2021-06-03 | 2021-08-18 | 株式会社ナボカルコスメティックス | 新規フェニルプロパノイド化合物 |
-
2021
- 2021-06-03 JP JP2021093326A patent/JP6919960B1/ja active Active
-
2022
- 2022-03-14 US US18/564,331 patent/US20240270779A1/en active Pending
- 2022-03-14 KR KR1020237033794A patent/KR20240017335A/ko active Pending
- 2022-03-14 CN CN202280030063.4A patent/CN117529487B/zh active Active
- 2022-03-14 EP EP22815624.6A patent/EP4349844A1/en not_active Withdrawn
- 2022-03-14 WO PCT/JP2022/011172 patent/WO2022254867A1/ja active Application Filing
- 2022-06-06 TW TW111120853A patent/TW202313063A/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011136969A (ja) * | 2009-12-29 | 2011-07-14 | Daiichi Kokusai Kagi Kofun Yugenkoshi | セツレンカ抽出物、飲食品組成物および基礎化粧品組成物 |
Non-Patent Citations (3)
Title |
---|
LEWIS, N. G. ET AL.: "EXCLUSIVE ACCUMULATION OF Z-ISOMERS OF MONOLIGNOLS AND THEIR GLUCOSIDES IN BARK OF FAGUS GRANDIFOLIA", PHYTOCHEMIST, vol. 27, JPN6021026981, 1988, pages 2119 - 2121, XP026615975, ISSN: 0004551033, DOI: 10.1016/0031-9422(88)80107-9 * |
MA, X. ET AL.: "Platycodon grandiflorum extract: chemical composition and whitening, antioxidant, and antiinflammato", RSC ADV., vol. 11, JPN6021026980, 15 March 2021 (2021-03-15), pages 10814 - 10826, ISSN: 0004551032 * |
ONO, M. ET AL.: "Antioxidative and Antihyaluronidase Activities of Some Fructus (Fruit of Foeniculum vulgare MILLER)", FOOD SCI. TECHNOL. INT., vol. 3, JPN6021026979, 1997, pages 53 - 55, XP002979116, ISSN: 0004551031 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117529487A (zh) * | 2021-06-03 | 2024-02-06 | 拿波佳尔股份有限公司 | 新颖苯丙素类化合物 |
CN117529487B (zh) * | 2021-06-03 | 2025-01-28 | 拿波佳尔股份有限公司 | 新颖苯丙素类化合物 |
Also Published As
Publication number | Publication date |
---|---|
WO2022254867A1 (ja) | 2022-12-08 |
KR20240017335A (ko) | 2024-02-07 |
US20240270779A1 (en) | 2024-08-15 |
EP4349844A1 (en) | 2024-04-10 |
CN117529487B (zh) | 2025-01-28 |
JP2022185604A (ja) | 2022-12-15 |
TW202313063A (zh) | 2023-04-01 |
CN117529487A (zh) | 2024-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022254867A1 (ja) | 新規フェニルプロパノイド化合物 | |
WO2022215441A1 (ja) | 新規ポリフェノール化合物 | |
JP6005900B2 (ja) | メラニン産生抑制剤及びメラニン産生抑制作用を有する医薬品、食品又は化粧料 | |
KR101453609B1 (ko) | 조팝나무잎으로부터 분리된 신규 헤미테르펜 글루코사이드 화합물 및 이의 항산화 및 항염 용도 | |
JP6923100B1 (ja) | 新規イソフラボン化合物 | |
JP5122147B2 (ja) | 抗酸化作用を有する2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシド | |
JP5620847B2 (ja) | 新規化合物、抗腫瘍剤及び抗腫瘍作用を有する医薬品、食品又は化粧料 | |
KR20100059375A (ko) | 아스퍼질러스 테리우스 추출물, 신규 부티로락톤 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 항산화용 조성물 | |
JP5122148B2 (ja) | 抗酸化作用を有する2−アシルフロログルシノール−4,6−ジ−C−β−D−グルコピラノシド | |
EP1840131B1 (en) | Novel polyphenol glycoside derived from acerola | |
KR102711584B1 (ko) | 신규한 항염증성 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 약학조성물 | |
KR20130135133A (ko) | 유동추출물, 이의 분획물 또는 이로부터 분리한 디테르펜 화합물을 유효성분으로 함유하는 피부노화 방지 및 개선용 약학적 조성물 | |
KR101309114B1 (ko) | 콩버섯으로부터 분리한 아이소인돌리논 계열의 항산화 화합물 및 이의 분리방법 | |
JP2004026760A (ja) | 癌細胞のアポトーシス誘導剤、その製造方法、それを有効成分とする抗癌剤、食品製剤及び化粧品 | |
KR101882876B1 (ko) | 방향족 케톤계 화합물, 이의 생산 방법, 및 용도 | |
KR20210154084A (ko) | 감귤 추출물을 유효성분으로 포함하는 화장료 조성물 | |
KR20220076568A (ko) | 양파로부터 쿼세틴의 함량이 증가된 양파 추출물을 생산하는 방법 | |
KR20030039143A (ko) | 젖비단그물버섯 유래의 신규한 벤조퓨란계 화합물 및 이를유효성분으로 하는 항산화 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210604 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210604 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210713 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210715 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6919960 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |